ECONOMIC EVALUATION OF IMIPENEM-CILASTATIN VERSUS DORIPENEM IN VENTILATORASSOCIATED PNEUMONIA IN EGYPT

Nermeen Ashoush

doi:10.22159/ajpcr.2017.v10i6.18066

Authors

Nermeen Ashoush Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, The British University in Egypt, El-Sherouk, Cairo 11837, Egypt. 2Health Economics Unit, Center for Drug Research and Development (CDRD), The British University in Egypt, El-Sherouk, Cairo 11837, Egypt.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i6.18066

Keywords:

Ventilator-associated pneumonia, Cost-effectiveness, Doripenem, Imipenem-cilastatin

Abstract

Objective: One of the most common complications of critical illness among surgical and trauma patients is ventilator-associated pneumonia (VAP). The mortality rate increases due to inappropriate empiric treatment of VAP. The rates of Pseudomonas aeruginosa (PA) VAP susceptibility to doripenem (DOR) are higher than those to imipenem-cilastatin (IMI). Cost-effectiveness analysis was developed to define outcome differences between strategies of empiric treatment of VAP with DOR versus IMI in Egyptian patients.

Methods: A cost-effectiveness model was designed comparing empiric treatment of VAP with DOR versus IMI from the health insurance perspectives. The differences in the total costs and quality-adjusted life years (QALYs) under each scenario were examined, and sensitivity analyses were conducted to determine the stability of our estimates. Drug costs were taken from health insurance hospitals, with other inputs derived from the literature.

Results: Deterministic baseline results from the model of DOR compared to IMI in the treatment of VAP suggest that DOR is more effective and less expensive than IMI. The total costs for IMI and DOR were Egyptian pound (EGP) 4646.93 and EGP 4197.58, respectively. QALYs for IMI and DOR were 0.53 and 0.54, respectively.

Conclusions: Given the microbiologic sensitivity profile of PA to DOR and IMI, and depending on the local susceptibility patterns in institutions where DOR in vitro susceptibilities are superior to those of other carbapenems for PA clinical isolates, empiric treatment of VAP with DOR may dominate that with IMI by being both life- and cost-saving.

Downloads

Download data is not yet available.

References

Liu B, Li SQ, Zhang SM, Xu P, Zhang X, Zhang YH, et al. Risk factors of ventilator associated pneumonia in a paediatric intensive care unit: A systematic review and meta-analysis. J Thorac Dis 2013;5(4):525-31.

Jaimes F, De La Rosa G, Gomez E, Munera P, Ramirez J, Castrillon S.Incidence and risk factors for ventilator-associated pneumonia in a developing country: Where is the difference? Respir Med 2007;101(4):762-7.

Urrea M, Pons M, Serra M, Latorre C, Palomeque A. Prospective incidence study of nosocomial infections in a pediatric intensive care unit. Pediatr Infect Dis J 2003;22(6):490-4.

Srinivasan R, Asselin J, Gildengorin G, Wiener-Kronish J, Flori HR. A prospective study of ventilator-associated pneumonia in children.Pediatrics 2009;123(4):1108-15.

Raza MW, Kazi BM, Mustafa M, Gould FK. Developing countries have their own characteristic problems with infection control. J Hosp Infect 2004;57(4):294-9.

Abdel-Gawad TA, El-Hodhod MA, Ibrahim HM, Michael YW. Gastroesophageal reflux in mechanically ventilated paediatric patients and its relation to ventilator-associated pneumonia. Crit Care 2009;13:R164.

Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165(7):867-903.

Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-acquired pneumonia study group. Intensive Care Med 1996;22(5):387-94.

Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122(1):262-8.

Sheikh-Taha M, Khoury T, Chatila M. Assessment of the appropriate utilization of impinem/cilastatin in a tertiary care hospital. Int J Pharm Pharm Sci 2011;3(4):381-3.

Jayapraba S, Suresh A, Niraimathi V. Forced oxidative degradation study of doripenem by UV spectrophotometric method. Int J Pharm Pharm Sci 2013;5(1):430-1.

American Thoracic Society; Infectious Diseases Society of America.Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416.

Brown N, Draghi DH, Yee YC, Evangelista AT, Sahm DF. Susceptibility of Pseudomonas aeruginosa to Doripenem and Imipenem in the United States: 2006-2007 TRUST Surveillance. Poster Presentation at the 37

Critical Care Congress. Honolulu, HI, February, 2-6; 2008.

Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. th Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008;36(4):1089-96.

Zilberberg MD, Mody SH, Chen J, Shorr AF. Cost-effectiveness model of empiric doripenem compared with imipenem-cilastatin in ventilatorassociated pneumonia. Surg Infect (Larchmt) 2010;11(5):409-17.

Edwards SJ, Campbell HE, Plumb JM. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 2006;7(1):72-8.

Brewer SC, Wunderink RG, Jones CB, Leeper KV. Ventilatorassociated pneumonia due to Pseudomonas

aeruginosa. Chest 1996;109:1019-29.18. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A,Fishman NO. Imipenem resistance among pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance onclinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27(9):893-900.

NNIS System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31(8):481-98.

Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS,Cox MJ, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical

center. Crit Care Med 2003;31(5):1312-7.